Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Rajesh Agarwal to Silymarin

This is a "connection" page, showing publications Rajesh Agarwal has written about Silymarin.

 
Connection Strength
  
 
 
21.293
  
  1. Rigby CM, Roy S, Deep G, Guillermo-Lagae R, Jain AK, Dhar D, Orlicky DJ, Agarwal C, Agarwal R. Role of p53 in silibinin-mediated inhibition of ultraviolet B radiation-induced DNA damage, inflammation and skin carcinogenesis. Carcinogenesis. 2017 01; 38(1):40-50.
    View in: PubMed
    Score: 0.475
  2. Deep G, Kumar R, Nambiar DK, Jain AK, Ramteke AM, Serkova NJ, Agarwal C, Agarwal R. Silibinin inhibits hypoxia-induced HIF-1a-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics. Mol Carcinog. 2017 03; 56(3):833-848.
    View in: PubMed
    Score: 0.472
  3. Tewari-Singh N, Agarwal R. Mustard vesicating agent-induced toxicity in the skin tissue and silibinin as a potential countermeasure. Ann N Y Acad Sci. 2016 06; 1374(1):184-92.
    View in: PubMed
    Score: 0.465
  4. Ting H, Deep G, Kumar S, Jain AK, Agarwal C, Agarwal R. Beneficial effects of the naturally occurring flavonoid silibinin on the prostate cancer microenvironment: role of monocyte chemotactic protein-1 and immune cell recruitment. Carcinogenesis. 2016 06; 37(6):589-599.
    View in: PubMed
    Score: 0.458
  5. Guillermo-Lagae R, Deep G, Ting H, Agarwal C, Agarwal R. Silibinin enhances the repair of ultraviolet B-induced DNA damage by activating p53-dependent nucleotide excision repair mechanism in human dermal fibroblasts. Oncotarget. 2015 Nov 24; 6(37):39594-606.
    View in: PubMed
    Score: 0.447
  6. Jain AK, Tewari-Singh N, Inturi S, Kumar D, Orlicky DJ, Agarwal C, White CW, Agarwal R. Flavanone silibinin treatment attenuates nitrogen mustard-induced toxic effects in mouse skin. Toxicol Appl Pharmacol. 2015 May 15; 285(1):71-8.
    View in: PubMed
    Score: 0.426
  7. Tilley C, Deep G, Agarwal C, Wempe MF, Biedermann D, Valentov? K, Kren V, Agarwal R. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation. Mol Carcinog. 2016 Jan; 55(1):3-14.
    View in: PubMed
    Score: 0.418
  8. Nambiar DK, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget. 2014 Oct 30; 5(20):10017-33.
    View in: PubMed
    Score: 0.415
  9. Deep G, Kumar R, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling. Mutat Res. 2014 Oct; 768:35-46.
    View in: PubMed
    Score: 0.413
  10. Kumar S, Raina K, Agarwal C, Agarwal R. Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget. 2014 Jul 15; 5(13):4972-89.
    View in: PubMed
    Score: 0.407
  11. Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, Cramer SD, Agarwal C, Agarwal R. Silibinin prevents prostate cancer cell-mediated differentiation of na?ve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF ?2. Mol Carcinog. 2015 Sep; 54(9):730-41.
    View in: PubMed
    Score: 0.396
  12. Deep G, Agarwal R. Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets. 2013 Jun; 13(5):486-99.
    View in: PubMed
    Score: 0.377
  13. Raina K, Agarwal R. Promise and potential of silibinin in colorectal cancer management: what patterns can be seen? Future Oncol. 2013 Jun; 9(6):759-61.
    View in: PubMed
    Score: 0.377
  14. Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013 Jul; 15(3):707-16.
    View in: PubMed
    Score: 0.373
  15. Agarwal C, Wadhwa R, Deep G, Biedermann D, Ga??k R, Kren V, Agarwal R. Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship. PLoS One. 2013; 8(3):e60074.
    View in: PubMed
    Score: 0.372
  16. Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther. 2013 May; 345(2):206-14.
    View in: PubMed
    Score: 0.370
  17. Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R. Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy. 2013 May; 9(5):697-713.
    View in: PubMed
    Score: 0.370
  18. Narayanapillai S, Agarwal C, Deep G, Agarwal R. Silibinin inhibits ultraviolet B radiation-induced DNA-damage and apoptosis by enhancing interleukin-12 expression in JB6 cells and SKH-1 hairless mouse skin. Mol Carcinog. 2014 Jun; 53(6):471-9.
    View in: PubMed
    Score: 0.368
  19. Mateen S, Raina K, Agarwal R. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer. 2013; 65 Suppl 1:3-11.
    View in: PubMed
    Score: 0.366
  20. Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-?B, and AP-1 activation in RAW264.7 cells. Mol Carcinog. 2014 Mar; 53(3):169-80.
    View in: PubMed
    Score: 0.362
  21. Tewari-Singh N, Jain AK, Inturi S, Agarwal C, White CW, Agarwal R. Silibinin attenuates sulfur mustard analog-induced skin injury by targeting multiple pathways connecting oxidative stress and inflammation. PLoS One. 2012; 7(9):e46149.
    View in: PubMed
    Score: 0.359
  22. Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 2012 Oct; 7(10):1161-72.
    View in: PubMed
    Score: 0.358
  23. Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R. Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicol Appl Pharmacol. 2012 Oct 01; 264(1):23-31.
    View in: PubMed
    Score: 0.355
  24. Narayanapillai S, Agarwal C, Tilley C, Agarwal R. Silibinin is a potent sensitizer of UVA radiation-induced oxidative stress and apoptosis in human keratinocyte HaCaT cells. Photochem Photobiol. 2012 Sep-Oct; 88(5):1135-40.
    View in: PubMed
    Score: 0.342
  25. Roy S, Deep G, Agarwal C, Agarwal R. Silibinin prevents ultraviolet B radiation-induced epidermal damages in JB6 cells and mouse skin in a p53-GADD45a-dependent manner. Carcinogenesis. 2012 Mar; 33(3):629-36.
    View in: PubMed
    Score: 0.340
  26. Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-?B signaling. Mol Carcinog. 2013 Mar; 52(3):195-206.
    View in: PubMed
    Score: 0.338
  27. Tyagi A, Agarwal C, Dwyer-Nield LD, Singh RP, Malkinson AM, Agarwal R. Silibinin modulates TNF-a and IFN-? mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog. 2012 Oct; 51(10):832-42.
    View in: PubMed
    Score: 0.333
  28. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila). 2011 Aug; 4(8):1222-32.
    View in: PubMed
    Score: 0.326
  29. Ramasamy K, Dwyer-Nield LD, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, Singh RP, Malkinson AM, Agarwal R. Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res. 2011 Feb 15; 17(4):753-61.
    View in: PubMed
    Score: 0.317
  30. Deep G, Gangar SC, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-?B, and androgen receptor signaling. Mol Carcinog. 2010 Oct; 49(10):902-12.
    View in: PubMed
    Score: 0.313
  31. Ravichandran K, Velmurugan B, Gu M, Singh RP, Agarwal R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res. 2010 Sep 15; 16(18):4595-606.
    View in: PubMed
    Score: 0.312
  32. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010 Sep; 29(3):447-63.
    View in: PubMed
    Score: 0.311
  33. Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G, Agarwal R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res. 2010 Oct; 27(10):2085-97.
    View in: PubMed
    Score: 0.308
  34. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia. 2010 May; 12(5):415-24.
    View in: PubMed
    Score: 0.304
  35. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, Agarwal R. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin. Int J Cancer. 2008 Dec 15; 123(12):2750-8.
    View in: PubMed
    Score: 0.276
  36. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 2008 Dec 01; 14(23):7773-80.
    View in: PubMed
    Score: 0.276
  37. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer. 2008 Jul 01; 123(1):41-50.
    View in: PubMed
    Score: 0.268
  38. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008 Oct 08; 269(2):352-62.
    View in: PubMed
    Score: 0.265
  39. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther. 2007 Dec; 6(12 Pt 1):3248-55.
    View in: PubMed
    Score: 0.257
  40. Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther. 2007 Jun; 6(2):130-45.
    View in: PubMed
    Score: 0.248
  41. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007 Jul; 28(7):1533-42.
    View in: PubMed
    Score: 0.245
  42. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol. 2007 Nov 01; 224(3):350-9.
    View in: PubMed
    Score: 0.239
  43. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 2006 Nov-Dec; 26(6B):4457-98.
    View in: PubMed
    Score: 0.239
  44. Dhanalakshmi S, Agarwal C, Singh RP, Agarwal R. Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells. J Biol Chem. 2005 May 27; 280(21):20375-83.
    View in: PubMed
    Score: 0.214
  45. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene. 2005 Feb 10; 24(7):1188-202.
    View in: PubMed
    Score: 0.212
  46. Singh RP, Agarwal R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004 Nov 02; 555(1-2):21-32.
    View in: PubMed
    Score: 0.208
  47. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res. 2004 Sep 01; 64(17):6349-56.
    View in: PubMed
    Score: 0.205
  48. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004 Sep; 25(9):1711-20.
    View in: PubMed
    Score: 0.201
  49. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004 Aug; 25(8):1459-65.
    View in: PubMed
    Score: 0.199
  50. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004 Feb; 11(2):493-9.
    View in: PubMed
    Score: 0.197
  51. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets. 2004 Feb; 4(1):1-11.
    View in: PubMed
    Score: 0.197
  52. Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glode LM, Agarwal R. Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochem Biophys Res Commun. 2003 Dec 26; 312(4):1178-84.
    View in: PubMed
    Score: 0.196
  53. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene. 2003 Nov 13; 22(51):8271-82.
    View in: PubMed
    Score: 0.194
  54. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Dual efficacy of silibinin in protecting or enhancing ultraviolet B radiation-caused apoptosis in HaCaT human immortalized keratinocytes. Carcinogenesis. 2004 Jan; 25(1):99-106.
    View in: PubMed
    Score: 0.193
  55. Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer. 2003 Sep 20; 106(5):699-705.
    View in: PubMed
    Score: 0.192
  56. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev. 2003 Sep; 12(9):933-9.
    View in: PubMed
    Score: 0.192
  57. Sharma G, Singh RP, Chan DC, Agarwal R. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res. 2003 May-Jun; 23(3B):2649-55.
    View in: PubMed
    Score: 0.187
  58. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal. 2002 Aug; 4(4):655-63.
    View in: PubMed
    Score: 0.178
  59. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2002 Jun 01; 62(11):3063-9.
    View in: PubMed
    Score: 0.176
  60. Tyagi A, Agarwal C, Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther. 2002 May; 1(7):525-32.
    View in: PubMed
    Score: 0.175
  61. Singh RP, Tyagi AK, Zhao J, Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis. 2002 Mar; 23(3):499-510.
    View in: PubMed
    Score: 0.173
  62. Goswami DG, Kant R, Tewari-Singh N, Agarwal R. Efficacy of anti-inflammatory, antibiotic and pleiotropic agents in reversing nitrogen mustard-induced injury in ex vivo cultured rabbit cornea. Toxicol Lett. 2018 Sep 01; 293:127-132.
    View in: PubMed
    Score: 0.128
  63. Nambiar DK, Rajamani P, Deep G, Jain AK, Agarwal R, Singh RP. Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling. Mol Cancer Ther. 2015 Dec; 14(12):2722-34.
    View in: PubMed
    Score: 0.111
  64. Tilley C, Deep G, Agarwal R. Chemopreventive opportunities to control basal cell carcinoma: Current perspectives. Mol Carcinog. 2015 Sep; 54(9):688-97.
    View in: PubMed
    Score: 0.108
  65. Sy-Cordero AA, Graf TN, Runyon SP, Wani MC, Kroll DJ, Agarwal R, Brantley SJ, Paine MF, Polyak SJ, Oberlies NH. Enhanced bioactivity of silybin B methylation products. Bioorg Med Chem. 2013 Feb 01; 21(3):742-7.
    View in: PubMed
    Score: 0.091
  66. Nambiar D, Prajapati V, Agarwal R, Singh RP. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer Lett. 2013 Jun 28; 334(1):109-17.
    View in: PubMed
    Score: 0.090
  67. Deep G, Gangar SC, Rajamanickam S, Raina K, Gu M, Agarwal C, Oberlies NH, Agarwal R. Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. PLoS One. 2012; 7(4):e34630.
    View in: PubMed
    Score: 0.087
  68. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res. 2010 Mar 15; 70(6):2368-78.
    View in: PubMed
    Score: 0.075
  69. Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog. 2010 Mar; 49(3):247-58.
    View in: PubMed
    Score: 0.075
  70. Sy-Cordero A, Graf TN, Nakanishi Y, Wani MC, Agarwal R, Kroll DJ, Oberlies NH. Large-scale isolation of flavonolignans from Silybum marianum extract affords new minor constituents and preliminary structure-activity relationships. Planta Med. 2010 Apr; 76(6):644-7.
    View in: PubMed
    Score: 0.074
  71. Rajamanickam S, Kaur M, Velmurugan B, Singh RP, Agarwal R. Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm Res. 2009 Dec; 26(12):2558-67.
    View in: PubMed
    Score: 0.073
  72. Singh RP, Agarwal R. Cosmeceuticals and silibinin. Clin Dermatol. 2009 Sep-Oct; 27(5):479-84.
    View in: PubMed
    Score: 0.073
  73. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther. 2009 Aug; 8(8):2366-74.
    View in: PubMed
    Score: 0.072
  74. Raina K, Serkova NJ, Agarwal R. Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study. Cancer Res. 2009 May 01; 69(9):3731-5.
    View in: PubMed
    Score: 0.071
  75. Singh RP, Raina K, Deep G, Chan D, Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res. 2009 Jan 15; 15(2):613-21.
    View in: PubMed
    Score: 0.070
  76. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM, Agarwal R. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila). 2009 Jan; 2(1):74-83.
    View in: PubMed
    Score: 0.069
  77. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila). 2008 Oct; 1(5):376-84.
    View in: PubMed
    Score: 0.068
  78. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008 Aug 15; 68(16):6822-30.
    View in: PubMed
    Score: 0.068
  79. Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther. 2008 Jul; 7(7):1817-26.
    View in: PubMed
    Score: 0.067
  80. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008 Mar 15; 68(6):2043-50.
    View in: PubMed
    Score: 0.066
  81. Tyagi A, Sharma Y, Agarwal C, Agarwal R. Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res. 2008 Sep; 25(9):2143-50.
    View in: PubMed
    Score: 0.065
  82. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res. 2008 Jan 01; 14(1):300-8.
    View in: PubMed
    Score: 0.065
  83. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glod? LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2007 Nov 15; 67(22):11083-91.
    View in: PubMed
    Score: 0.064
  84. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis. 2007 Dec; 28(12):2567-74.
    View in: PubMed
    Score: 0.064
  85. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther. 2007 Oct; 6(10):2696-707.
    View in: PubMed
    Score: 0.064
  86. Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin. 2007 Sep; 28(9):1466-75.
    View in: PubMed
    Score: 0.063
  87. Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007 Apr 01; 67(7):3483-91.
    View in: PubMed
    Score: 0.061
  88. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis. 2007 Jul; 28(7):1463-70.
    View in: PubMed
    Score: 0.061
  89. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glod? LM. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 Apr; 25(2):139-46.
    View in: PubMed
    Score: 0.060
  90. Gu M, Singh RP, Dhanalakshmi S, Mohan S, Agarwal R. Differential effect of silibinin on E2F transcription factors and associated biological events in chronically UVB-exposed skin versus tumors in SKH-1 hairless mice. Mol Cancer Ther. 2006 Aug; 5(8):2121-9.
    View in: PubMed
    Score: 0.059
  91. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006 Jun 21; 98(12):846-55.
    View in: PubMed
    Score: 0.058
  92. Tyagi A, Singh RP, Agarwal C, Agarwal R. Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis. 2006 Nov; 27(11):2269-80.
    View in: PubMed
    Score: 0.058
  93. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog. 2006 Jun; 45(6):436-42.
    View in: PubMed
    Score: 0.058
  94. Singh RP, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther. 2006 May; 5(5):1145-53.
    View in: PubMed
    Score: 0.058
  95. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005 Dec 01; 11(23):8441-8.
    View in: PubMed
    Score: 0.056
  96. Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005 Sep; 41(13):1969-79.
    View in: PubMed
    Score: 0.055
  97. Gu M, Dhanalakshmi S, Singh RP, Agarwal R. Dietary feeding of silibinin prevents early biomarkers of UVB radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Cancer Epidemiol Biomarkers Prev. 2005 May; 14(5):1344-9.
    View in: PubMed
    Score: 0.054
  98. Gu M, Dhanalakshmi S, Mohan S, Singh RP, Agarwal R. Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis. 2005 Aug; 26(8):1404-13.
    View in: PubMed
    Score: 0.054
  99. Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res. 2004 Dec 15; 10(24):8641-7.
    View in: PubMed
    Score: 0.052
  100. Qi L, Singh RP, Lu Y, Agarwal R, Harrison GS, Franzusoff A, Glode LM. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther. 2003 Sep-Oct; 2(5):526-31.
    View in: PubMed
    Score: 0.048
  101. Flaig TW, Glod? M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55.
    View in: PubMed
    Score: 0.019
  102. Flaig TW, Su LJ, Harrison G, Agarwal R, Glod? LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 01; 120(9):2028-33.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)